Arbutin

Arbutin at a Glance

Arbutin is the hydroquinone glucoside that defines bearberry (uva-ursi), and it is also present in pear and wheat.

It has two quite separate uses. As a tyrosinase inhibitor it is a skin-lightening agent with small human trials in melasma — particularly the more potent alpha-arbutin. And it is the basis of bearberry’s traditional role as a urinary antiseptic, where the glucoside is hydrolysed to hydroquinone and excreted in urine.

That second mechanism is also the source of its safety ceiling: hydroquinone is the active agent and the reason exposure is kept short.

What It's Used For

Arbutin is a hydroquinone glucoside — a pro-drug that is largely inert until β-glucosidase (in gut, tissue, skin or bacteria) hydrolyses it to free hydroquinone, the species that carries both its activity and its safety concern. It has two distinct faces. In cosmetics it is a tyrosinase-inhibiting skin-lightening agent — the synthetic α-arbutin anomer is more potent than the natural plant β-arbutin ^{3,4Reference 3Maeda K et al. · 1996Arbutin: mechanism of its depigmenting action in human melanocyte cultureView study →Reference 4Sugimoto K et al. · 2004Inhibitory effects of α-arbutin on melanin synthesis in cultured human melanoma cellsView study →} — with small human melasma trials behind it ^{5,6Reference 5Ertam I et al. · 2008RCTEfficiency of ellagic acid and arbutin in melasma: a randomised, prospective, open-label studyView study →Reference 6Tantanasrigul P et al. · 2025RCTTopical α-arbutin 5% and kojic acid 2% versus triple-combination cream for melasma: a split-face RCTView study →}.

In herbal medicine it is the near-exclusive active of bearberry (uva-ursi) as a urinary antiseptic, where the arbutin delivered to urine is cleaved to hydroquinone at the site of infection ^{1Reference 1Schindler G et al. · 2002Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uva-ursiView study →}.

The load-bearing point throughout: the hydroquinone exposure, not arbutin itself, is the pharmacologically and toxicologically decisive quantity.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Isolate human data are limited to small combination cosmetic trials, so scores stay modest. Each application links to its write-up.

01Skin lighteningPromising50%Small human melasma RCTs (mostly α-arbutin) + melanocyte mechanism ^{3,4,5,6Reference 3Maeda K et al. · 1996Arbutin: mechanism of its depigmenting action in human melanocyte cultureView study →Reference 4Sugimoto K et al. · 2004Inhibitory effects of α-arbutin on melanin synthesis in cultured human melanoma cellsView study →Reference 5Ertam I et al. · 2008RCTEfficiency of ellagic acid and arbutin in melasma: a randomised, prospective, open-label studyView study →Reference 6Tantanasrigul P et al. · 2025RCTTopical α-arbutin 5% and kojic acid 2% versus triple-combination cream for melasma: a split-face RCTView study →}

02Urinary antiseptic (bearberry)Shaky40%Human PK confirming urinary hydroquinone delivery; mechanism preclinical ^{1,2,10Reference 1Schindler G et al. · 2002Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uva-ursiView study →Reference 2Quintus J et al. · 2005Urinary excretion of arbutin metabolites after oral administration of bearberry-leaf extractView study →Reference 10de Arriba SG et al. · 2013Risk assessment of free hydroquinone derived from Arctostaphylos uva-ursi folium herbal preparationsView study →}

03AntioxidantShaky28%In-vitro radical scavenging ^{7Reference 7Boo YC · 2021Arbutin as a skin-depigmenting agent with antimelanogenic and antioxidant propertiesView study →}

04Anti-inflammatoryShaky26%Cell/rodent NF-κB suppression ^{8Reference 8Lee HJ · 2012Anti-inflammatory effects of arbutin in LPS-stimulated BV2 microglial cellsView study →}

Mechanisms

Pharmacokinetics

Arbutin is a phenolic glycoside hydrolyzed by β-glucosidase — in the gut microbiota, intestinal/hepatic tissue and skin — to free hydroquinone, which is then conjugated to glucuronide and sulfate. After oral bearberry, over 60% of the arbutin dose is recovered in urine as hydroquinone conjugates, with free hydroquinone appearing within hours, and the conversion is pH-sensitive (favored in alkaline, blunted in acidic urine) ^{1,2Reference 1Schindler G et al. · 2002Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uva-ursiView study →Reference 2Quintus J et al. · 2005Urinary excretion of arbutin metabolites after oral administration of bearberry-leaf extractView study →}. Topically, skin β-glucosidase can likewise release small amounts of hydroquinone from applied arbutin — the mechanism behind both efficacy and the regulatory trace-hydroquinone concern. The systemic and urinary hydroquinone exposure, not arbutin, is the load-bearing quantity.

Clinical trials

Human data are two small, combination-formula cosmetic-dermatology studies — an open-label melasma RCT of 3% arbutin ^{5Reference 5Ertam I et al. · 2008RCTEfficiency of ellagic acid and arbutin in melasma: a randomised, prospective, open-label studyView study →} and a split-face RCT of α-arbutin-plus-kojic-acid ^{6Reference 6Tantanasrigul P et al. · 2025RCTTopical α-arbutin 5% and kojic acid 2% versus triple-combination cream for melasma: a split-face RCTView study →}. There is no robust isolated-arbutin monotherapy RCT and no modern controlled urinary-infection trial; the bearberry human record is pharmacokinetic (confirming urinary hydroquinone delivery), not efficacy ^{1,2Reference 1Schindler G et al. · 2002Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uva-ursiView study →Reference 2Quintus J et al. · 2005Urinary excretion of arbutin metabolites after oral administration of bearberry-leaf extractView study →}.

Last checked: July 2026.

Toxicity & Safety

Arbutin’s safety is not really arbutin’s at all — it is hydroquinone’s, the regulated aglycone it hydrolyses to, which is why it is flagged moderate rather than low.

Safety at a Glance

⚠️ Moderate toxicity

• Releases free hydroquinone. A regulated skin-lightener, banned from OTC cosmetics in the EU and restricted by the US FDA.
• Contraindicated in pregnancy and breastfeeding. Also in children under 12 and renal impairment.
• Chronic use risks exogenous ochronosis. Paradoxical bluish-black pigmentation, alongside irritation and high-exposure genotoxicity signals.
• Oral use adds systemic exposure. Bearberry is a short-course herb, not a long-term one.
• Capped topical cosmetic use is regarded as safe. The EU SCCS judged α-arbutin acceptable to ~2% on the face if free hydroquinone stays at trace levels.

Full Safety & Interactions Detail

The whole safety picture is governed by hydroquinone, arbutin’s hydrolysis product — which is why it is flagged moderate rather than low. Hydroquinone is a regulated skin-lightening agent, banned from over-the-counter cosmetics in the EU and restricted/withdrawn from OTC use by the US FDA, with documented concerns over exogenous ochronosis (paradoxical bluish-black pigmentation with chronic use), skin irritation, and genotoxicity/rodent-carcinogenicity signals at high exposure; arbutin-derived hydroquinone is cytotoxic and pro-oxidant to human bladder cells at high dose in vitro ^{11Reference 11Huđek Turković A et al. · 2022Proteome changes in human bladder T24 cells induced by hydroquinone derived from ArctostaphylosView study →}.

In regulatory context, the EU SCCS judged α-arbutin safe in cosmetics up to ~2% (face) provided free hydroquinone is kept to unavoidable trace levels ^{9Reference 9SCCS · 2016Opinion on the safety of the use of α-arbutin in cosmetic productsView study →}, and a risk assessment of bearberry products estimated free-hydroquinone urinary exposure at ~11 µg/kg/day at therapeutic dose, used to argue that short-course bearberry is tolerable ^{10Reference 10de Arriba SG et al. · 2013Risk assessment of free hydroquinone derived from Arctostaphylos uva-ursi folium herbal preparationsView study →}.

So capped topical cosmetic use is regarded as safe, but the hydroquinone dependency — dose, formulation purity, chronic use (ochronosis/genotoxicity), and added systemic exposure with oral use — means arbutin cannot be treated as inert. (Its own preclinical literature is otherwise organ-protective — nephroprotective in acute kidney injury ^{12Reference 12Zhang B et al. · 2021Arbutin attenuates LPS-induced acute kidney injuryView study →}, anti-proliferative in bladder cancer cells ^{13Reference 13Li H et al. · 2011Arbutin inhibits TCCSUP human bladder cancer cell proliferation via up-regulation of p21View study →}, and gastroprotective in rat ulcer models ^{14Reference 14Taha MME et al. · 2012Gastroprotective activities of Turnera diffusa: role of arbutinView study →}.)

Dosage

There is no established safe long-term or isolated oral dose, and nothing here is a recommendation. Topically, trials used β-arbutin ~3% gel and α-arbutin 2–5% (within EU cosmetic caps of ~2% face for α-arbutin), usually combined with kojic/ellagic acid and a sunscreen over 8–12 weeks ^{5,6,9Reference 5Ertam I et al. · 2008RCTEfficiency of ellagic acid and arbutin in melasma: a randomised, prospective, open-label studyView study →Reference 6Tantanasrigul P et al. · 2025RCTTopical α-arbutin 5% and kojic acid 2% versus triple-combination cream for melasma: a split-face RCTView study →Reference 9SCCS · 2016Opinion on the safety of the use of α-arbutin in cosmetic productsView study →}. Orally, as bearberry (not the isolate), pharmacopoeial dosing is standardized to arbutin content and limited to no more than about five consecutive days and a few courses a year, with urine alkalinized to aid conversion and use contraindicated in pregnancy, lactation, children and renal disease ^{10Reference 10de Arriba SG et al. · 2013Risk assessment of free hydroquinone derived from Arctostaphylos uva-ursi folium herbal preparationsView study →}.

References

1. Schindler G, et al. (2002). Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uva-ursi. Journal of Clinical Pharmacology. https://pubmed.ncbi.nlm.nih.gov/12162475/
2. Quintus J, et al. (2005). Urinary excretion of arbutin metabolites after oral administration of bearberry-leaf extract. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/15729623/
3. Maeda K, Fukuda M, et al. (1996). Arbutin: mechanism of its depigmenting action in human melanocyte culture. Journal of Pharmacology and Experimental Therapeutics. https://pubmed.ncbi.nlm.nih.gov/8632348/
4. Sugimoto K, et al. (2004). Inhibitory effects of α-arbutin on melanin synthesis in cultured human melanoma cells. Biological & Pharmaceutical Bulletin. https://pubmed.ncbi.nlm.nih.gov/15056856/
5. Ertam I, et al. (2008). Efficiency of ellagic acid and arbutin in melasma: a randomised, prospective, open-label study. The Journal of Dermatology. https://pubmed.ncbi.nlm.nih.gov/18837701/
6. Tantanasrigul P, et al. (2025). Topical α-arbutin 5% and kojic acid 2% versus triple-combination cream for melasma: a split-face RCT. Journal of Cosmetic Dermatology. https://pubmed.ncbi.nlm.nih.gov/39555866/
7. Boo YC (2021). Arbutin as a skin-depigmenting agent with antimelanogenic and antioxidant properties. Antioxidants (Basel). https://pubmed.ncbi.nlm.nih.gov/34356362/
8. Lee HJ, Kim KW (2012). Anti-inflammatory effects of arbutin in LPS-stimulated BV2 microglial cells. Inflammation Research. https://pubmed.ncbi.nlm.nih.gov/22487852/
9. SCCS (2016). Opinion on the safety of the use of α-arbutin in cosmetic products. Regulatory Toxicology and Pharmacology. https://pubmed.ncbi.nlm.nih.gov/26646661/
10. de Arriba SG, et al. (2013). Risk assessment of free hydroquinone derived from Arctostaphylos uva-ursi folium herbal preparations. International Journal of Toxicology. https://pubmed.ncbi.nlm.nih.gov/24296864/
11. Huđek Turković A, et al. (2022). Proteome changes in human bladder T24 cells induced by hydroquinone derived from Arctostaphylos. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/35143933/
12. Zhang B, et al. (2021). Arbutin attenuates LPS-induced acute kidney injury. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/33494001/
13. Li H, et al. (2011). Arbutin inhibits TCCSUP human bladder cancer cell proliferation via up-regulation of p21. Die Pharmazie. https://pubmed.ncbi.nlm.nih.gov/21612160/
14. Taha MME, et al. (2012). Gastroprotective activities of Turnera diffusa: role of arbutin. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/22374081/

View all 14 references▾